MACROGENICS INC
No SEC Form 4 filings for $MGNX in the last 30 days.
See all $MGNX insider activity →MacroGenics reported positive Phase 1 results for MGC026, showing a 27% response rate in SCCHN patients. The company plans to start a front-line combination study with pembrolizumab in early 2027. The data suggests potential for earlier-line use, pending further trials.
MacroGenics has dosed the first patient in a Phase I trial for MGC030, an antibody-drug conjugate targeting advanced solid tumors. The trial will assess pharmacokinetics, safety, and antitumour activity. The company expects to enroll up to 54 patients initially, with potential expansion. According to MacroGenics, preclinical data showed encouraging antitumour activity.
On Aug. 11, Gilead Sciences (GILD) exercised an option to exclusively license a preclinical solid-tumor bispecific program using MacroGenics’ (MGNX) TRIDENT platform, triggering a $10 million milestone. The 2022 collaboration covers three programs, including clinical-stage MGD024, with up to $1.6 billion in milestones plus royalties. Financially, MGNX reported $20.8M Q1 revenue and $154.2M cash; GILD reported $7.8B Q2 revenue and raised 2026 product sales guidance to $29.8B–$30.1B.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning MGNX (MACROGENICS INC). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent MGNX coverage spans financial news, corporate actions and mergers & acquisitions.
Positive early‑stage data may lift the stock as investors price in potential later‑line expansion.
The start of a Phase I trial introduces a potential new therapy but no efficacy data yet.
Near-term catalyst is the $10M milestone and renewed validation of TRIDENT, but the article frames it as non-dilutive support rather than a clinical inflection.
The 8-K combines financial datapoints with balance-sheet support (pro forma cash $327M) and operational restructuring (outsourced manufacturing), which can re-rate near-term risk and runway.
The $10M option-exercise payment is a near-term cash inflow and de-risks continued collaboration activity, supporting sentiment for MGNX.
AlphAI scores every news story that mentions MGNX with an AI model for sentiment and relevance, and aggregates insider trades from MACROGENICS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
MacroGenics reported positive Phase 1 results for MGC026, showing a 27% response rate in SCCHN patients. The company plans to start a front-line combination study with pembrolizumab in early 2027. The data suggests potential for earlier-line use, pending further trials.
2 min readMacroGenics has dosed the first patient in a Phase I trial for MGC030, an antibody-drug conjugate targeting advanced solid tumors. The trial will assess pharmacokinetics, safety, and antitumour activity. The company expects to enroll up to 54 patients initially, with potential expansion. According to MacroGenics, preclinical data showed encouraging antitumour activity.
2 min readOn Aug. 11, Gilead Sciences (GILD) exercised an option to exclusively license a preclinical solid-tumor bispecific program using MacroGenics’ (MGNX) TRIDENT platform, triggering a $10 million milestone. The 2022 collaboration covers three programs, including clinical-stage MGD024, with up to $1.6 billion in milestones plus royalties. Financially, MGNX reported $20.8M Q1 revenue and $154.2M cash; GILD reported $7.8B Q2 revenue and raised 2026 product sales guidance to $29.8B–$30.1B.
4 min readMACROGENICS INC (MGNX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position • Announced sale of manufacturing operations (July 2026) for $122.5 million and transition to fully outsourced model with leaner, approximately
6 min readMacroGenics (NASDAQ:MGNX) shares rose 4.3% after hours after Gilead Sciences exercised an option on a preclinical bispecific program under their 2022 collaboration, triggering a $10 million payment. Gilead holds an exclusive license using MacroGenics’ TRIDENT platform targeting two undisclosed solid tumor targets. MacroGenics may receive up to about $1.6 billion more in milestones and royalties.
2 min readMacroGenics said it reached a $10 million milestone after Gilead exercised an option to license a preclinical bispecific program, according to the company. The announcement links the payment to Gilead’s licensing decision and may affect MacroGenics’ near-term cash flows and pipeline monetization.
1 min readMACROGENICS INC (MGNX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. mgnx-20260701 0001125345 FALSE 0001125345 2026-07-01 2026-07-01 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported):
2 min readMACROGENICS INC (MGNX) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-99.2 3 exhibit99-2proforma.htm EX-99.2 Document Exhibit 99.2 MACROGENICS, INC. UNAUDITED CONSOLIDATED PRO FORMA FINANCIAL INFORMATION Effective as of June 30, 2026, MacroGenics, Inc. (the “Company”) completed the previously announced sale (the “Closing”) of certain assets and
4 min readSanofi SA (SNY) said it will appoint Paulo Fontoura as EVP and Global Head of R&D Pharma effective Sept. 1, reporting to CEO Belen Garijo and succeeding Houman Ashrafian. Separately, MacroGenics said it is entitled to $24.5M in regulatory milestone payments from Sanofi after FDA accelerated approval of TZIELD (teplizumab) for children.
4 min readBora Pharmaceuticals (TWSE:6472; OTCQX:BORAY) said it completed its acquisition of MacroGenics’ Rockville, Maryland GMP biologics drug-substance facility and a Frederick warehousing center for $122.5m via Bora Biologics USA. Bora also signed a long-term CDMO service agreement with MacroGenics. Bora Biologics now has 20,000L SUB capacity across US sites and Taiwan.
3 min read
